Collaborating in clinical trials
One of GMS’s five goals is increased participation in clinical trials. MEGALiT, a precision medicine clinical study, is a collaborative investment in promoting clinical trials in Sweden. GMS also welcomes collaboration with other clinical studies.
The collaboration between GMS and MEGALiT gathers resources and expertise that contribute to the implementation of precision medicine at national level and to creating access to equitable care and greater opportunities for patients to participate in clinical research.
The precision medicine project A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT) was initiated in 2017. The project includes a clinical study that provides opportunities to learn about the implementation of precision medicine in multicentre environments, as well as several development projects implemented within the study in close collaboration between the healthcare service, academia and industry. The initiative is under the leadership of Uppsala University Hospital.
The clinical study began on a small scale as a proof of concept at two university hospitals, in Uppsala and Gothenburg, during autumn 2020. The study will be expanded to more clinics, initially at university hospitals. The aim is a national establishment in collaboration with local clinical research units and GMS.
In phase one, 154 patients with locally advanced or metastatic solid tumours will be screened for possible treatment within the study. The screening will be based on which treatable genetic changes are detected in a recently taken sample from the patient’s tumour. The next phase will also include patients with blood cancers. The study is a multicentre phase II study and a combined umbrella and basket trial.
The clinical study constitutes a testbed for four separate development projects, all designed to improve precision medicine processes. This includes the planning and implementation of clinical trials, handling biomaterials, communication and interaction between patients and healthcare professionals, as well as the generation of real-world data.
Collaboration within the framework of MEGALiT is open to additional partners and we welcome dialogue. Please contact us at: email@example.com
If you are a patient or next of kin, you should first contact your doctor or, alternatively, you can find information about MEGALiT (in Swedish) here.